Clinical Trials Logo

Filter by:
NCT ID: NCT03958097 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Pilot Study of NK Cell Combined With PD-1 Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer

Start date: May 17, 2019
Phase: Phase 2
Study type: Interventional

PD-1 antibody has been approved as second line therapy for driven mutation negative non-small cell lung cancer, but overall response rate is only between 15-20%. Basic study found NK cell can enhance anti-tumor ability of PD-L1 antibody. This study evaluates the efficacy and safety of NK cell combined with PD-1 antibody for advanced driven mutation negative non-small cell lung cancer (NSCLC) as second-line therapy.

NCT ID: NCT03957720 Recruiting - Wilson's Disease Clinical Trials

The Individual Therapy for Patients With Wilson's Disease

Start date: March 15, 2019
Phase: Early Phase 1
Study type: Interventional

Based on the genotype characteristics and genotype-phenotype-treatment prognosis data of Chinese WD patients, this study intends to further optimize the treatment regimen of Chinese WD patients and formulate individualized treatment regimens for each genotype, so as to further improve the prognosis of patients.

NCT ID: NCT03957707 Recruiting - Clinical trials for Basal Ganglia Haematoma

Sterotactic Operation Integrating With Thrombolysis in Basal Ganglion Hemorrhage Evacuation

SOITBE
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Spontaneous cerebral hemorrhage is one of the main causes of death and disability all over the world, accounting for 20%-30% of all cerebrovascular diseases. Minimally invasive surgery of cerebral hemorrhage, especially puncture aspiration, can improve early and long-term neurological recovery in patients with cerebral hemorrhage. Until now, no standardized practice for minimally invasive surgery of spontaneous cerebral hemorrhage has been established. Hematoma puncture and drainage based on CT scans without precise localization and personalized approach design, which may lead to poor efficacy and high risk of complications. Our hospital has much experience in treating cerebral hemorrhage with stereotactic puncture and aspiration. So we conduct a prospective multicenter randomized controlled clinical trial to determine the therapeutic effects of puncture aspiration plus thrombolysis treatment for the perioperative and long-term recovery of patients with small to moderate hematoma in deep basal ganglia via computerized precision coordinates and personalized approach design.

NCT ID: NCT03957655 Not yet recruiting - Liver Cirrhosis Clinical Trials

Safety and Efficacy of SHED for Decompensated Liver Cirrhosis

Start date: June 1, 2019
Phase: Early Phase 1
Study type: Interventional

This study is an prospective, randomized control study. Patients with decompensated cirrhosis will be randomly assigned to receive 2 times of SHED treatment plus standard medical care(treatment)or 4 times of SHED treatment plus standard medical care(treatment)or standard medical care (control). The primary outcome is MELD-Na score. Secondary outcomes are Child-Pugh, liver function, life quality, cytokine levels, cell subsets and survival.

NCT ID: NCT03957642 Recruiting - Optic Disk Drusen Clinical Trials

Systematic Imaging Examination in ODD

Start date: June 1, 2019
Phase:
Study type: Observational

To evaluate the diagnostic value of systematic ophthalmologic imaging examination in the diagnosis of embedded optic disc drusen (ODD) in adolescents with mild visual impairment.

NCT ID: NCT03957603 Recruiting - Clinical trials for Gestational Diabetes Mellitus

Medical Nutrition Therapy Combined With TPF-DM in Pregnant Women With Gestational Diabetes Mellitus

Start date: May 16, 2019
Phase: N/A
Study type: Interventional

Background: Gestational diabetes mellitus (GDM), GDM is the first time of gestational impaired glucose tolerance in pregnant women. It is the most common complication disease in women of childbearing age. It is associated with the high risk of adverse health outcomes for both mothers and offsprings and the variety of metabolic disease, including type 2 diabetes, etc. As for the epidemiology data of GDM in China, the prevalence is around 18% based on the criteria from the International Association of Diabetes in Pregnancy Study Groups, IADPSG. Several studies claimed that the diabetes-specific formula improved glycemic control in type 2 diabetes patients. However, the effects of medical nutrition therapy combined with the diabetes-specific formula in pregnant women with gestational diabetes mellitus (GDM) are unclear. Objective: This study examines whether medical nutrition therapy combined with Enteral Nutrition Suspension (TFP-DM, Diason 0.75 kcal/ml) in GDM women could improve the glycemic control and the pregnancy outcomes.

NCT ID: NCT03957590 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma (ESCC)

Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Patient With ESCC

Start date: July 30, 2019
Phase: Phase 3
Study type: Interventional

This is a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to compare the efficacy and safety of BGB-A317 versus Placebo with chemoradiotherapy in Patients with Localized Esophageal Squamous Cell Carcinoma.

NCT ID: NCT03957564 Recruiting - Gastric Cancer Clinical Trials

Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer

Start date: May 20, 2019
Phase: Phase 2
Study type: Interventional

To explore the clinical value of dynamic detection of circulating tumor cells(CTCs), circulating tumor DNA(ctDNA) and cell-free DNA(cfDNA) in neoadjuvant chemotherapy and operation of resectable or locally advanced gastric or gastro-oesophageal junction cancer.

NCT ID: NCT03956953 Recruiting - Autoimmune Diseases Clinical Trials

Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects

Start date: April 8, 2019
Phase: Phase 1
Study type: Interventional

Main objective of this study is to assess BMS-986165 plasma PK following single and multiple oral doses of BMS-986165 in healthy Chinese subjects.

NCT ID: NCT03956823 Not yet recruiting - Hypertension Clinical Trials

Clinical Efficacy of Telmisartan in Reducing Cardiac Remodeling Among Obese Patients With Hypertension

Start date: June 1, 2019
Phase: N/A
Study type: Interventional

Hypertension is closely related to metabolic abnormalities such as obesity, dyslipidemia and diabetes. When hypertension is complicated with metabolic abnormalities, target organ damage is more serious, the risk of cardiovascular adverse events is greater, and the treatment is more complex. The pathophysiological mechanism of obesity-associated hypertension has its particularity. Blood pressure control and effective control of obesity are important therapeutic targets. At present, there are no guidelines for the treatment of obesity-associated hypertension. Although several drugs have certain effects on fat metabolism, they have little effect on blood pressure and have some side effects in long-term use. Among the existing antihypertensive drugs, angiotensin II type 1 receptor (AT-1) antagonists have shown their particularity in improving glycolipid metabolism, but strict clinical trials are needed to confirm their effectiveness in weight loss and metabolism improvement. Previous studies have shown that obese patients with hypertension have severe insulin resistance, poor glycolipid metabolism and are prone to cardiovascular damage. Telmisartan can block AT-1 receptor and partially activate PPAR-γ, increase the expression of PPAR-γ target gene in preadipocytes, improve the function of visceral adipose tissue, and effectively prevent obesity-related cardiovascular diseases. It is presumed that telmisartan can act as a PPAR-γ agonist in clinic by altering the metabolic components and insulin sensitivity, but there is no clinical evidence for this. On the basis of previous studies, this study aims to evaluate the clinical efficacy of telmisartan or amlodipine in controlling blood pressure, reducing fat accumulation, improving insulin sensitivity, and reducing cardiac remodeling in obese patients with hypertension by prospective cohort study.